Acción GTHX G1 THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas G1 Therapeutics, Inc.

Acciones

GTHX

US3621LQ1099

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 25/06/2024 		Varia. Cinco días. Varia. 1 de enero.
2,2 USD -0,90 % Gráfico intradía de G1 Therapeutics, Inc. -14,06 % -27,87 %
24/06 Principales caídas del mediodía MT
24/06 Actualización del sector: Los valores del sector sanitario avanzan el lunes antes de la comercialización MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Top Midday Decliners
Sector Update: Health Care Stocks Advance Premarket Monday
US Equity Futures Mixed in Premarket Action as Traders Eye Friday's Inflation Data
Top Premarket Decliners
G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints
G1 Therapeutics' breast cancer drug fails in late-stage trial
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer
G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024
TScan Therapeutics, Inc Announces Board and Committee Changes
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 THERAPEUTICS, INC. - MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL AND TOLERABILITY OBSERVED IN PATIENTS RECEIVING TRILACICLIB IN COMBINATION WITH A TROP2 ANTIBODY-DRUG CONJUGATE
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
G1 Therapeutics, Inc. Announces the Presentation of Mature Phase 2 Clinical Trial Results
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting
G1 THERAPEUTICS TO PARTICIPATE IN TD COWEN'S 5TH ANNUAL ONCOLOGY INNOVATION SUMMIT
G1 THERAPEUTICS AND DEIMOS BIOSCIENCES ANNOUNCE GLOBAL LICENSE AGREEMENT FOR LEROCICLIB FOR RADIOPROTECTIVE USES
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción GTHX
  4. Noticias G1 Therapeutics, Inc.
  5. Otros idiomas